Introduction
Systemic lupus erythematosus (SLE) is a heterogeneous multiorgan autoimmune disease characterized by the production of autoantibodies (auto-Abs) against nuclear components and cell surface antigens. The aetiology of SLE is still unclear, with environmental, hormonal and stochastic factors in combination with multiple genes determining both susceptibility and disease phenotype. Genetic susceptibility appears to be a major contributor to the disease development and considerable progress has recently been made in identifying SLE loci and candidate genes in humans. [1] [2] [3] [4] [5] [6] Similar efforts in mice have led to the identification of more than 30 genomic intervals associated with susceptibility to SLE or SLE-related phenotypes distributed among 21 nonoverlapping regions. 7 These studies have highlighted considerable genetic heterogeneity, epistatic interactions and different sets of loci for different autoimmune traits, illustrating the complexity of the disease.
Comparison of the various linkage studies performed in lupus-prone strains has demonstrated that at least some susceptibility loci are shared among the lupus-prone strains. In particular, one region, located on distal chromosome 1, has shown strong linkage in several murine studies. This locus, named Sle1, 8 Sle16 9 and Nba2 10, 11 according to the strain of origin (New Zealand White, 129 and New Zealand Black, respectively), when expressed on the C57BL/6 (B6) genetic background, has been shown to induce a relatively benign autoimmune phenotype characterized by progressive loss of immune tolerance that leads to auto-Ab production, an expanded population of activated T and B cells, splenomegaly and hypergammaglobulinemia. Recent work by Wandstrat et al. 12 demonstrated that the break in tolerance to nuclear antigens mediated by the Sle1 subcongenic locus, Sle1b, is associated with functional polymorphisms (haplotype II) in the SLAM/CD2 family of immune receptor genes and that these polymorphisms are found in the majority of inbred strains examined, including the non-autoimmune 129 strain. The notion that introducing the haplotype II SLAM locus into the B6 genome dramatically increases the susceptibility for lupus was confirmed by our studies with the B6.129Chr1 congenic mice. 9, 13 In these studies, we showed that introgressing the chromosome 1 interval from 129 into B6 background was sufficient to cause a loss of immune tolerance resulting in the production of Abs against nuclear antigens. These findings raised two important questions: (1) to what extent is this 129 locus contributing to the autoimmune phenotype displayed by knockout animals in which a gene located in this region has been inactivated in 129 embryonic stem cells (for example, (2) why does the 129 strain remain non-autoimmune despite the presence of a potent SLE-related SLAM/CD2 haplotype on chromosome 1?
Our original genome-wide scan analysis 9 identified a B6 locus (termed Sle18) in the mid-distal portion of chromosome 3 contributing to antinuclear Ab production. Subsequently these results were confirmed in a larger data set obtained by combining the data from different cohorts of (129 Â B6)F2 mice. 19 To test whether this B6 locus was one of the key epistatic modifiers in the lupus-prone (129 Â B6) strain and to determine the contribution of this B6 interval to lupus pathogenesis, we generated a 129 congenic strain carrying, on chromosome 3, a B6 region encompassing the Sle18 locus. Phenotypic analysis of this newly generated congenic strain, 129.B6-Sle18, indicates that the B6 Sle18 locus interacts with 129 gene(s) to mediate earlier expansion of activated B220 þ and CD4 þ T-cell populations, accelerated autoimmunity and mild glomerulonephritis. These results together with our earlier findings provide a further example of the manner in which epistatic interactions can lead to autoimmunity in the (129 Â B6) hybrid strain, a combination frequently created in gene-targeted animals.
Results

Serological analysis of 129.B6-Sle18 congenic mice
We have previously shown that a B6 region on chromosome 3 between D3Mit13 and D3Mit278 is strongly linked to antinuclear Ab production in (129 Â B6)F2 mice. 9, 19 This locus has been named Sle18. In an attempt to determine the contribution of Sle18 to the development of auto-Abs, this portion of the B6 chromosome 3 was transferred to the 129 background as congenic using a marker-assisted selection protocol. After eight generations of backcrosses, over 99% of the genome in these mice was of 129 origin and a congenic line (referred to as 129.B6-Sle18; Figure 1 ) was created. At the end of the backcrossing, additional microsatellite analyses were carried out in the congenic mice to exclude the presence of unselected B6 genomic regions. Congenic female mice (n ¼ 33) together with matched 129 (n ¼ 29) and B6 (n ¼ 12) controls were monitored at regular intervals for the presence of lupus traits up to 12 months of age. At the age of 1 year , all animals were killed, renal histology assessed and splenic cells analysed by fluorescenceactivated cell sorter (FACS).
Serological analyses of the cohorts of mice revealed significant changes in the 129.B6-Sle18 mice compared with the controls by 4 months of age. , range 0-1.1; anti-chromatin Abs: median 0 AEU ml À1 , range 0-5.9). During the course of a 1-year follow-up, a progressive increase in the level of the different Abs was observed in all experimental groups and this was reflected in the final analysis. Thus, only the final results are presented in full ( Table 1 ). The 129.B6-Sle18 mice displayed markedly elevated levels of all auto-Abs measured, and these, most likely, contributed to the elevation of total immunoglobulin M (IgM) and IgG. Interestingly, the 129.B6-Sle18 mice showed strikingly increased levels of Abs against nuclear antigens and also had Abs against extractable nuclear antigens indicating they produce Abs targeting a broad spectrum of autoantigens, as is typical of SLE patients. In this context it is of note that the 129 mice appear to display considerable levels of anti-Abs against extractable nuclear antigens when compared to the B6 controls, consistent with a low grade of autoimmunity.
Renal assessment
At the age of 12 months, all mice were killed and kidneys processed for light microscopy. The amount of proteinuria assessed by dipsticks was negligible and did not reveal any significant difference between the congenic group and the B6 or 129 mice (data not shown). However, histological analysis of the renal sections showed evidence of proliferative glomerulonephritis in the 129.B6-Sle18 animals (Figures 2a and b) , which was statistically more pronounced than in the kidneys of 129 or B6 animals (Po0.001; Figure 2c ). However, there was no mortality by 1 year of age in any of the experimental cohorts.
Phenotypic and functional analysis of splenic cell populations To begin to assess cellular components contributing to the breach in tolerance to nuclear antigens, we performed a comprehensive analysis of the various splenic subpopulations. Spleen cells of at least seven mice from each experimental cohort were analysed by FACS at the age of 6 months, a time point in which the congenic mice had already developed autoimmune traits. As shown in Table 2 , there were numerous quantitative differences in the percentages of various splenic subpopulations between the 129.B6-Sle18 mice and age-and gendermatched 129 controls.
A small but significant decrease (Po0.05) in the percentage of T lymphocytes (CD90.2 þ CD19 À ) was observed in the congenic mice. As has been shown previously in other lupus models, the 129.B6-Sle18 mice had a highly significant increase in the percentage of Table 2 and Figure 3c) . Interestingly, the increase in memory T cells (CD44 high ) was already present in the congenic mice at the age of 2 months (129.B6-Sle18: 23.35 ± 0.9, n ¼ 13, vs 129: 19.78 ± 0.5, n ¼ 15, P ¼ 0.0057). At this time point, no other alterations in splenic subpopulations were observed (data not shown). Such shifts to activated and memory CD4 populations have been observed in a variety of lupus models, although with differing kinetics, and they seem to correlate with the development but not necessarily the severity of autoimmunity. [20] [21] [22] [23] [24] [25] Surprisingly, in the autoimmune 129.B6-Sle18 animals, we found a marked increase (Po0.01) in the percentage of regulatory T cells (Tregs), defined as being CD4 þ Foxp3 positive, when compared with the non-autoimmune strains (129 and B6). This expansion of the Foxp3 þ occurred in both the CD25 þ and CD25 À fractions (Table 2 ) and, interestingly, was accompanied by a decrease in mean fluorescence intensity for Foxp3 þ in the CD4 þ population (50 ± 1.2 in 129 mice vs 41±1.7 in the 129.B6-Sle18 animals, P ¼ 0.0041; Figure 3d) .
Similar to what was observed in the T-cell compartment, in the 129.B6-Sle18 mice, there was also a striking increase in the percentage of B cells expressing the activation marker CD69 (16.7 ± 0.8% in 129.B6-Sle18 mice vs 11.2 ± 0.8% in 129 mice, Po0.001; Table 2 and Figure 3b ). This expansion of the activated B-cell compartment was also accompanied by a perturbation in the proportion of marginal and follicular zone (FZ) B cells. As previously reported in other autoimmune strains, 26, 27 the percentage of marginal zone (MZ) B cells was significantly decreased (17.9 ± 0.5% in 129 vs 14.8±1.0% in 129.B6-Sle18 mice, Po0.05), and this was reflected by an increase in the FZ B cells (39.9 ± 0.9% in In aged 129.B6-Sle18 mice, there was also a small but significant increase in the number of the plasmocytes (Po0.05; Table 2 ). Notably, the alterations in MZ and FZ B cells and the expansion in the fraction of activated B cells were not observed in young predisease mice at 2 months of age indicating that these B-cell abnormalities did not precede the overall immune dysregulation. We also analysed the splenic B1-cell population and found a marked increase in this B-cell lineage in the congenic mice when compared with the controls (Po0.01), as observed in other lupus models. 28, 29 Altogether, These results indicated that the introgression of the B6 chromosome 3 region on the 129 genetic background affected both the T-and B-cell lineages.
Having identified such a wide range of T-and B-cell perturbations in the 129.B6-Sle18 congenic mice, we then began to investigate the function of these cells. No differences were found in the ex vivo proliferation of naïve T cell on anti-CD3 plates or in the proliferation and/or activation of B cells upon stimulation with either LPS or anti-IgM or anti-CD40 ± IL-4 (data not shown). We also analysed the cellular response of the 129.B6-Sle18-derived CD4 þ T cells by measuring the Ca 2 þ flux levels induced by T cell receptor complex stimulation. This analysis again failed to reveal any measurable differences between the 129.B6-Sle18 and the 129 animals (data not shown). Surprised by the observation of the reduced mean fluorescence intensity for Foxp3 þ in the congenic CD4 þ population, we compared the functional competency of the Tregs using an in vitro suppressor assay as previously described. 
Candidate gene analysis
The 129.B6-Sle18 mice harbour a B6 interval of B90 Mb. This region is densely packed with genes with known immunological significance and potential relevance to SLE pathogenesis. Many were attractive candidate genes; however, we initially selected the Cd2 gene for screening because it belongs to the SLAM/CD2 family whose members, located in the Sle1 locus, have been strongly implicated in the pathogenesis of SLE. 12 In addition, the gene encoding the human CD2 is located in the short arm of chromosome 1 at band 1p13, a region that has been linked to SLE by an association study in humans. 31 The Cd2 gene is located at position B101.1 Mb on mouse chromosome 3 near the peak of our linkage ( Figure 1 ). We sequenced all five coding exons of the Cd2 gene, including the splice junctions as well as B330 and B500 bp of the 5 0 and 3 0 untranslated regions, and found no polymorphisms between 129 and B6 strains. In addition, FACS analysis of CD2 expression on splenic T and B cells failed to reveal any measurable difference between the 129.B6-Sle18 congenic mice and the 129 control at the age of 6 months (CD4 þ T cell: 442.4 ± 12.8 mean fluorescence intensity, n ¼ 7, in the 129.B6-Sle18 vs 434.4 ± 7.1, n ¼ 7, in the 129 mice; B220 þ B cell: 355.5 ± 9.0 mean fluorescence intensity, n ¼ 7, in the 129.B6-Sle18 vs 356.4 ± 5.5, n ¼ 7, in the 129 mice).
Discussion
Although it has previously been demonstrated that interactions of 129 genes on chromosome 1 (Sle16) and the B6 background lead to the development of autoimmunity, the contributions of B6 loci to this phenotype remained unknown. This study demonstrates for the first time that a B6 locus on chromosome 3 (Sle18) can play a key role in lupus pathogenesis in this model by inducing Abs against a broad spectrum of autoantigens, expansion of activated CD4 þ T and B cells and mild glomerulonephritis.
Genetic modelling of the inheritance of lupus susceptibility in our original testcross of 129 and B6 mice 9, 19 indicated that disease development would require B6 loci in combination with 129-derived genes, primarily on chromosome 1. Consistent with this prediction, here, we have shown that the introgression of Sle18 into the 129 genetic background was sufficient to mediate several autoimmune traits. Unlike the loci on chromosomes 1 and 7, this B6 locus has not been consistently linked to lupus disease traits, as all the other SLE-associated loci identified on chromosome 3 (Sles3 and Bxs5) were proximal (between 20-40 cM) to our observed linkage peak (B51 cM). Thus, it was important to validate the initial linkage data with a congenic approach and this study has achieved this. Interestingly, Sles3 and Bxs5 both involve non-autoimmune strains; in the case of Sles3, NZWxC57BL/6 heterozygosity 7 and in the case of Bxs5, C57BL/10 homozygosity. 32 The confirmation of Sle18 (in combination with 129-derived genes) as an important SLE modifier highlights further the likelihood of epistatic interactions influencing the phenotype of knockout strains, in spite of extensive backcrossing to B6. In this context, it is of note that we have previously reported another B6-derived locus, linked to anti-dsDNA Abs, on the mid-distal region of chromosome 4. 9 Although this observation has not been confirmed as yet in a congenic strain, we cannot exclude that additional B6-derived loci contribute to the autoimmune traits observed when the Sle16 locus is expressed in the B6 strain. 13 The cellular phenotypes of the 129.B6-Sle18 mice share common features with other murine lupus models indicating that the underlying processes leading to these alterations are essential for the development of systemic autoimmunity. Most notably, Sle18 caused a marked increase in the proportion of activated and memory T lymphocytes, a trait that has already been observed in B6.129Chr1 13 and B6.Sle1 congenic strains. 33 
Spontaneous CD4
þ T-cell activation in autoimmune strains has been previously described in the literature and might be the consequence of a hyper responsiveness of T cells from lupus-prone mice to T-cell receptor engagement. 34 However, under our experimental conditions, the Sle18-derived CD4 þ T cells failed to show an increased Ca 2 þ flux in response to TCR stimulation. Tregs and specifically CD4 þ CD25 þ T cells expressing the Foxp3 transcription factor have been reported to play a key role in the maintenance of selftolerance. 35 Reduced Treg numbers as well as defective Treg function have been directly linked with autoimmune pathogenesis in multiple diseases including SLE. [36] [37] [38] A reduction in the overall number of Foxp3 þ Tregs has been reported in B6.Sle1 mice 39, 40 and a significant decrease in the percentage of CD4 þ CD25
high Tregs was also observed in the 1-year-old B6.129Chr1b mice. 13 However, in the B6.Sle1 mice, the reduction of Tregs was found in young mice before the appearance of auto-Abs, 39 whereas in the B6.129chr1b mice, no alterations in the percentage of Foxp3 þ Tregs was detected in the predisease stage. 13 Furthermore, a Teff resistance has been previously reported in the B6.Sle1 mice 40 and in other lupus models. Pertubations in splenic B-cell subsets have also been described in several lupus prone models. Although an increase in the MZ has been linked most tightly with the NZB-derived loci, 41 differences have been observed between B6 and NZW mice. In this study, we observed a reduction in the percentage of the MZ B cells accompanied by an increase in the proportion of FZ B cells. These findings would suggest that in the aged 129.B6-Sle18 mice, there was an increased antigenic stimulation resulting in an enhanced B-cell proliferation in the germinal centres. Of relevance to this is the observation that in young predisease mice, we did not find an expansion in the activated B cells or alterations in the splenic B subsets, whereas at this stage, the mice already showed an expansion of the memory T cells (CD25   -CD44 high CD4 þ ), indicating that the B-cell abnormalities may be secondary to the autoimmune dysregulation.
Despite multiple serological and cellular abnormalities, the 129.B6-Sle18 mice developed only relatively mild lupus glomerulonephritis confirming observations in other lupus models that additional gene(s) may be necessary to promote end-organ damage. Interestingly, the 129.B6-Sle18 mice, in contrast to the previous B6 congenic line (B6.129Chr1), contained not only the 129-derived Sle16 on chromosome 1 but also the 129-derived locus on proximal chromosome 7, previously shown to be linked to glomerulonephritis. 19 The presence of this additional 129-derived lupus locus had a small but significant impact on the renal phenotype supporting a multistep pathogenesis model in which the development of severe lupus nephritis requires the contribution of additional B6 gene(s) in combination with the 129-derived loci. Our original linkage analysis defined a single B6-derived locus associated to glomerulonephritis on proximal chromosome 13 that had a less penetrant effect than the locus on chromosome 7. 19 Nevertheless, we cannot exclude the possibility that such minor loci may have a significant influence on the renal disease in combination with the other SLE loci. Further experiments will be necessary to test this possibility.
Given the length of B6 fragment in the 129.B6-Sle18 mice (B90 Mb), it is not surprising that it contains several genes of potential immunological relevance for SLE pathogenesis. Thus, determining the causative gene is going to be quite a challenge. Sequence and expression analysis has shown that Cd2, a strong candidate gene, is unlikely to be the culprit gene. Further, the fine mapping of this locus and the generation and phenotypic analysis of congenic recombinants will allow us to progressively narrow the Sle18 interval so as to permit the identification and characterization of the disease gene within this region. Because the telomeric region of chromosome 1 has been shown to be key for the initiation of SLE in different murine lupus, identification of the gene(s) interacting with this region could provide insights useful for the understanding of the mechanisms involved in the disease pathogenesis. 
Materials and methods
Mice
A 129 congenic line (named 129. B6-Sle18) (Figure 1 ) was generated by backcrossing the chromosome 3 B6 interval into the 129 strain using microsatellite markers polymorphic between 129 and C57BL/6 mice. The average marker density was one marker per 10 cM across the autosomes, the positions and sequences of which were determined from the Mouse Genome Informatics database (http://www.informatics.jax.org). Only female animals were studied. In all, 33 129.B6-Sle18 congenic mice along with 29 129 and 12 B6 controls were followed up to the age of 1 year. Animals were kept under specific pathogen-free conditions. All animal care and procedures were conducted according to the institutional guidelines.
Serological analyses
The assays described below were conducted using serum obtained from the different cohorts at 4, 6 and 12 months of age:
(i) Levels of IgG antinuclear Ab were sought by indirect immunofluorescence using Hep-2 cells and a fluorescein-conjugated IgG Fc-specific antimouse Ab (Sigma-Aldrich, Dorset, UK). Serum samples were screened at a 1/80 dilution in phosphate-buffred saline supplemented with 2% bovine serum albumin, 0.05% Tween 20, 0.02% NaN3 and the positive samples titrated to end point. (ii) Anti-dsDNA, anti-ssDNA, anti-chromatin, anti-Ro, anti-La, anti-Sm Abs were measured by enzyme-linked immunosorbent assay (ELISA). Briefly, microtitre plates were coated with ssDNA (10 mg ml À1 ; Sigma-Aldrich) or chromatin (5 mg ml
À1
, Lorne Laboratories, Reading, UK) or Ro (10 U ml À1 ) or La (10 mg ml À1 ) or Sm (5 U ml À1 ) (Arotec Diagnostic Ltd, Wellington, New Zealand), samples were screened at 1/100 and bound Abs were detected with alkaline phosphataseconjugated goat antimouse IgG (g-chain specific; SigmaAldrich). The results were expressed as AEU (arbitrary ELISA units) relative to a standard positive sample derived from an MRL/Mp.lpr/lpr mice pool. (iii) Total serum IgM and IgG levels were assayed by capture ELISA. Briefly, microtitre plates were coated with goat antimouse Ig (H þ L) (5 mg ml
; Southern Biotechnology Associates Inc., Birmingham, AL, USA), serum samples were diluted appropriately in phosphate-buffered saline supplemented with 2% bovine serum albumin, 0.05% Tween 20, 0.02% NaN3 and incubated over night. Bound Abs were detected with alkaline phosphatase -conjugated goat antimouse IgG (g-chain specific; SigmaAldrich) or antimouse IgM (Southern Biotechnology Associates Inc., Birmingham, AL, USA). Serial dilutions of a known amount of isotype-specific Ig standard were added to each plate for quantification. (iv) Rheumatoid factor activity was measured by ELISA as described previously. 42 Microtitre plates were coated with 5 mg ml
(4-hydroxy-3-iodo-5-nitrophenyl; NIP) acetyl-conjugated bovine serum albumin, followed by a mouse IgG2a l anti-NIP Ab (NIP-23). 43 The plates were then incubated with appropriately diluted sera, and the assay was developed with alkaline phosphatase -conjugated rat antimouse k-chain mAb (H139.52.1; Southern Biotechnology Associates Inc., Birmingham, AL, USA). The results were expressed as optical density.
Renal assessment All the mice were killed at the age of one year. Proteinuria was assessed using Haema-combistix (Bayer Diagnostics, Newbury, UK). Urine samples were graded 0 to þ þ þ þ , corresponding to approximate protein concentration as follows: 0/trace ¼ o0. 30 
. Kidney tissue was fixed in Bouin's solution for at least 2 h, transferred into 70% ethanol, and then processed into paraffin. Sections were cut, mounted, stained with periodic acid-Schiff reagent and scored for glomerulonephritis. Glomerular histology was graded as follows: grade 0, normal; grade 1, focal hypercellularity in 10-25% of the glomeruli; grade 2, hypercellularity involving 450% of the glomerular tuft in 25-50% of glomeruli; grade 3, hypercellularity involving 450% of the glomerular tuft in 50-75% of glomeruli and grade 4, glomerular hypercellularity in 475% or crescents in 425% of glomeruli. Histological analysis was performed in a blinded manner.
Flow cytometry
Flow cytometry was performed using a three or four colour staining protocol on spleen cells and analysed with a FACSCalibur (Becton-Dickinson, Mountain View, CA, USA). The following Abs were used: anti-CD3 (145-2C11), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-CD11b (M1-70), anti-CD11c (HL-3), anti-CD19 (1D3), anti-CD21/CD35 (7G6), anti-CD23 (B3B4), anti-CD25 (PC61), anti-CD44 (IM7), anti-CD62L (MEL-14), antiPan-NK (anti-CD49b) (DX5), anti-CD69 (H1.2F3), anti-CD86 (B7-2), anti-CD90.2 (53-2.1) and anti-CD138 (281-2). All Abs were purchased from BD Biosciences Pharmingen (San Diego, CA, USA) with the exception of antiFoxp3 (FJK-16s) (eBioscience, San Diego, CA, USA). Biotinylated Abs were detected using an allophycocyanin-conjugated streptavidin Ab (BD Biosciences Pharmingen). Staining was performed in the presence of saturating concentration of 2.4G2 monoclonal Ab (antiFcgRII/III). For the intracellular staining, cells were fixed and lysed with the reagents and the protocol provided with the anti-Foxp3 Ab (eBioscience). Data were analysed using the FlowJo software version 6.4 (TreeStar Inc., Ashland, OR, USA).
Calcium flux analysis
Calcium flux analysis was performed as described previously. 12 Briefly, splenic cells from the 2-month-old 129 (n ¼ 2) and 129.B6-Sle18 (n ¼ 2) mice were enriched for T cells by negative selection using pan B (B220) magnetic beads (Dynal, Oslo, Norway). A total of 10 6 cells were labelled with 2 mM Fluo-3 AM (Molecular Probes, OR, USA) at 37 1C for 30 min. Experimental runs were performed on the FACSCalibur (Becton-Dickinson). Biotin TCRb-chain (H57-597), biotin CD4 (L3T4) and biotin CD8a (53-6.7) (Pharmingen-Becton Dickinson, San Diego, CA, USA) were added, followed by cross-linking with streptavidin (Roche, Mannbelm, Germany). Ionomycin was added to obtain the maximal response, whereas the minimal response was obtained by adding MnCl 2 . Analysis was performed on FlowJo software version 6.4 (TreeStar Inc., Ashland, OR, USA) and data were obtained from three independent experiments.
Cell proliferation assay Purified T cells were negatively sorted from 129 or 129.B6-Sle18 mice and then activated with plate-bound anti-CD3 (from 0.1 to 10 mg ml , Alexis biochemicals, Lausen, Switzerland) ±IL-4 (10 ng ml À1 , R&D Systems, Minneapolis, MN, USA ). After 18 h, cells were phenotyped with Abs to CD19, CD69 and CD86. After 48 and 72 h, production of IgM and IgG were measured in the supernatants by ELISA. Each assay included at least three mice per group and the experiments were repeated three times.
Isolation of CD4
þ CD25 þ T cells and coculture with CD4 þ CD25 À T cells This assay was performed as described previously. 30 Briefly, spleens and selected lymph nodes were macerated through a cell strainer and then treated with red cell lysis buffer. Negative magnetic selection of CD4 þ T cells was performed using DynaBeads (Dynal, Oslo, Norway) accordingly to the manufacturer's instructions. CD4 þ CD25 þ T cells were positively selected on Mini-MACS columns (Miltenyi, Bergish Gladbach, Germany), using Streptavidin MicroBeads (Miltenyi). The resulting cell purity was more than 90% as determined by flow cytometry. Purified CD4 þ CD25 þ T cells were cultured, in 96-well round-bottomed plates, with CD25 À T cells in the presence of Epoxy DynaBeads (one bead per five cells; Dynal) coated with anti-CD3 and anti-CD28 mAb. CD4 þ CD25 þ T cells purified from either the 129 or the 129.B6-Sle18 mice were added to 129 CD25 À T cells at a different Treg/Teff ratio ranging from 1:1 to 1:32. Crossover and syngeneic cocultures were also performed.
Irradiated CD25
À T cells were used as control. After 3 days, the incorporation of tritiated thymidine ( 3 H-TdR; Amersham Biosciences, Roosendaal, The Netherlands) over 16 h was measured. In addition, CD25
À T cells were prelabelled with CFSE (0.5 mM; Molecular Probes) and cultured in the presence of Epoxy DynaBeads (one bead per five cells; Dynal) coated with anti-CD3 and anti-CD28 mAb, either alone or with Treg, at different ratios. The cocultures of Teff/Treg ratio were incubated for 96 h, after which the proliferation of T cells was analysed by flow cytometry. All assays were performed with RPMI 1640 supplemented with 100 U ml À1 penicillin/streptomycin (Gibco, Paisley, UK), 2 mM L-glutamine (Gibco), 10 mM HEPES (Gibco) and 10% (volume/volume) heatinactivated fetal calf serum.
Statistics
Non-parametric data are presented as median, with range of values in parentheses unless otherwise stated. Statistics were calculated using GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA, USA). One-way analysis of variance with Bonferonni's multiple comparison tests were applied for analysis of multiple groups. Data from in vitro assays were analysed by two-tailed Student's t-test for unpaired samples. Differences were considered significant for P-values o0.05.
